EGFR and neuroendocrine neoplasm: Importantly, FGFR1 gene gain was also found in 11.4% of non-squamous tumors, including true gene amplification in about 7% of adenocarcinoma patients with never smoking history - the same population with an increased likelihood of harboring EGFR mutations or ALK rearrangements - and 11% among neuroendocrine tumors.